Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent MBT Plasma for Early COVID-19 Treatment
NCT04621123Phase 2Completed
- Start
- Nov 2020
- Primary completion
- May 2021
- Modality
- Plasma product, Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of convalescent anti-SARS-CoV-2 MBT plasma in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoints: Hospitalization Rate at 4 weeks and SARS-CoV-2 Viral Load at 1 week. Started Nov 2020; status: completed.
02
Drugs
convalescent anti-SARS-CoV-2 MBT plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04621123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04621123.